2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Suspended
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Conditions
Hematologic Neoplasms
4
Neutropenia
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Lymphoma
2
Leukemia
2
Infections
2
Fever
2
Febrile Neutropenia
2
Waldenstrom Macroglobulinemia
1
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Respiratory Distress Syndrome
1
Renal Insufficiency, Chronic
1
Recurrence
1
Pulmonary Arterial Hypertension
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia, Viral
1
Pneumonia
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Pain
1
Interventions
siltuximab
4
tocilizumab
3
fludarabine
3
Cyclophosphamide
3
fludarabine phosphate
2
Interleukin 1 Receptor Antagonist Protein
2
AP 1903 reagent
2
talquetamab
1
otelixizumab
1
obinutuzumab
1
lopinavir-ritonavir drug combination
1
glofitamab
1
axicabtagene ciloleucel
1
Piperacillin, Tazobactam Drug Combination
1
Oxygen Inhalation Therapy
1
Oxaliplatin
1
Neuropsychological Tests
1
Metoprolol
1
Methylprednisolone
1
Magnetic Resonance Spectroscopy
1
Lopinavir
1
Leukapheresis
1
Infliximab
1
Hydroxychloroquine
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Gelsolin
1
Etanercept
1
Dexamethasone
1
Contrast Media
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cytokine Release Syndrome
×
Piperacillin, Tazobactam Drug Combination
×
Clear all
NCT04394182
2022-03-29
ULTRA-COVID
Fundacion GenesisCare
Phase NA
Suspended
15 enrolled